Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prulifloxacin.

Susan J Keam1, Caroline M Perry

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 1, 2004
PubMed
Summary
This summary is machine-generated.

Prulifloxacin, a prodrug of ulifloxacin, is a broad-spectrum antibiotic effective against many Gram-negative and some Gram-positive bacteria. Clinical trials show good efficacy and tolerability for treating respiratory and urinary tract infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icotrokinra: First Approval.

Drugs·2026
Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026
Same author

Sevabertinib: First Approval.

Drugs·2026
Same author

Retlirafusp Alfa: First Approval.

Drugs·2026
Same author

Zeprumetostat: First Approval.

Drugs·2025
Same author

Brensocatib: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Prulifloxacin is an oral fluoroquinolone prodrug, metabolized to ulifloxacin.
  • It possesses a broad spectrum of activity and a long elimination half-life, permitting once-daily dosing.

Purpose of the Study:

  • To evaluate the in vitro activity and clinical efficacy of prulifloxacin.
  • To assess its tolerability profile in patients with bacterial infections.

Main Methods:

  • In vitro susceptibility testing against various clinical bacterial isolates.
  • Clinical trials evaluating prulifloxacin in patients with acute exacerbations of chronic bronchitis, complicated lower urinary tract infections (UTIs), and acute uncomplicated lower UTIs.

Main Results:

Related Experiment Videos

  • Ulifloxacin demonstrated broad-spectrum activity against Gram-negative bacteria (e.g., Escherichia coli, Klebsiella spp.) and susceptible Gram-positive organisms (e.g., Staphylococcus aureus, Enterococcus spp.).
  • Prulifloxacin showed good clinical and bacteriological efficacy, comparable to other antibiotics, in treating respiratory and urinary tract infections.
  • The drug was generally well tolerated, with a safety profile similar to ciprofloxacin.

Conclusions:

  • Prulifloxacin is an effective and well-tolerated oral antibacterial agent for treating specific respiratory and urinary tract infections.
  • Its broad spectrum of activity and convenient dosing regimen make it a valuable therapeutic option.